Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group
Molin L, the Calcipotriol-UVB Study Group
Dermatology 1999;198(4):375-381
clinical trial
3/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

BACKGROUND: Calcipotrial has a well-documented effect in the treatment of psoriasis. OBJECTIVE: To confirm the beneficial effect of the combination of calcipotriol and UVB and to demonstrate that the combination is safe and well tolerated. METHODS: Data from two randomized right/left studies were analysed. Patients included in the studies had chronic stable plaque-type psoriasis with symmetrical lesions on the arms, the legs and/or the trunk. In one study, 101 patients were treated with calcipotriol on one side and calcipotriol+UVB on the other side of the body (open study). In the other study, 77 patients were treated with calcipotriol+UVB on one side and vehicle+UVB on the other side of the body (double-blind study). Calcipotriol ointment, 50 g/g, was applied twice daily and UVB 3 times weekly for 8 weeks. UVB was increased from 0.7 MED before treatment in rapid steps up to the erythema threshold. RESULT: In both treatment series the therapeutic effect of the combination of calcipotriol and UVB was enhanced as compared to calcipotriol alone and UVB alone. In the first series there was a significant reduction of the psoriasis area and severity index (PASI) with the combination after 2 weeks as compared to calcipotriol alone. At the end of treatment significantly more sides were cleared after calcipotriol+UVB than after calcipotriol alone. In the other series there was a significantly faster onset of improvement on the sides treated with calcipotriol+UVB than on those treated with vehicle+UVB. After 2 weeks there was a significant difference in PASI in favour of calcipotriol+UVB. At the end of treatment, however, there was no difference between the treatments. There was a similar adverse event profile with either treatment. The addition of UVB to calcipotriol did not alter the tolerability or safety of topically applied calcipotriol. CONCLUSIONS: The result indicates a beneficial effect of combining calcipotriol and phototherapy. The findings are compared to other published studies.

Full text (sometimes free) may be available at these link(s):      help